Toothache Clinical Trial
Official title:
Cannabidiol (CBD) for the Management of Emergency Dental Pain
The purpose of this study is to evaulate CBD as a therapeutic approach for dental pain. Eligible subjects presented with emergency dental pain will be give a single dose of Epidiolex (FDA-approved CBD) or placebo and will be monitored for 3 hours for pain symptoms and psychologic effects.
CBD is a non-psychoactive, non-addictive compound of cannabis that has shown analgesic and anti-inflammatory properties. Epidiolex is the only FDA-approved oral CBD solution and will be the drug of choice in this study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02463552 -
Naproxen on Tooth Sensitivity Caused by In-office Bleaching
|
N/A | |
| Completed |
NCT00474175 -
Benzocaine Gel Toothache Dose-Response Study
|
Phase 4 | |
| Completed |
NCT00720057 -
Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.
|
Phase 3 | |
| Completed |
NCT02630771 -
Multimodal Assessment of Sensory Processing and Brain Features in Patients With Chronic Orofacial Pain
|
||
| Completed |
NCT00281684 -
SB-705498 Dental Pain Study After Tooth Extraction
|
Phase 2 | |
| Completed |
NCT00574015 -
The Comparison of Supraperiosteal Nerve Block With Opiate Analgesia in Alleviating the Pain of Toothache
|
Phase 4 | |
| Recruiting |
NCT06216951 -
Post-Operative Pain After Vital Pulpotomy in Molars With Symptomatic Pulpitis
|
||
| Completed |
NCT03153657 -
Piroxicam-beta-Cyclodextrin on Tooth Sensitivity Caused by In-office Bleaching
|
Phase 3 | |
| Terminated |
NCT02862691 -
Percocet vs. Bupivicaine for Toothaches in the ED
|
Phase 2 |